Stockreport

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Holdings Inc.  (ALXO) 
PDF ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high [Read more]